AM
AMIT KUMAR MITRA
Auburn University, Celgene Corp, Central Drug Research Institute, University of Calcutta, University of Minnesota
0000-0003-4046-7070
Employment
-
Auburn University Associate Professor2024 - Present
-
Auburn University Assistant Professor (Tenure-track)2017 - 2024
-
Celgene Corp Senior Scientist2017 - 2017
-
University of Minnesota Assistant Professor (Research)2013 - 2017
Education
-
Central Drug Research Institute PhD (Jawaharlal Nehru University)2004 - 2009
-
University of Calcutta M.Sc (Cytogenetics and Molecular Biology -Special Paper)2001 - 2003
Projects & Funding
Projects & funding information is unavailable.
Publications (81)
- Inhibition of BIRC5 and MCL-1 as a potential treatment strategy to overcome drug resistance in Mantle Cell Lymphoma Save
- Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance Save
- Inhibition of BIRC5 and MCL1 as a potential treatment strategy to overcome drug resistance in Mantle Cell Lymphoma Save
- Clofazimine Treatment Modulates Key Non-Coding RNAs Associated with Tumor Progression and Drug Resistance in Lethal Prostate Cancer Save
- Clofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate Cancer Save
- Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma Save
- Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial–Mesenchymal Transition Save
- Sample average treatment effect on the treated analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma Save
- Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer Save
- Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative Save